FDA Accepts Anesiva, Inc.'s Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated...
                   
biospace.com     May 21, 2008            

SOUTH SAN FRANCISCO, Calif., May 21 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV - News) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's electronic supplemental New Drug Application (sNDA) filing to expand the indication for Zingo to treat pain... [read full story]                    


View all news articles about*:
Anesiva Care Health Pain Patients Swelling
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

Anesiva: Painless Going Forward? (Zacks.com)

yahoo.com     Aug 12, 2008          

Tuesday August 12, 2:41 pm ET By Jason Napodano, CFA We are pleased to see that Anesiva, Inc. (NasdaqGM: ANSV - News) finally launched Zingo on June 30, 2008. We see the product as having at least $200 million potential in the...                    

comments

InterWest Partners Announces Closing of $650 Million Venture Fund

prnewswire.com     Aug 11, 2008   5 related          

InterWest's 10th Fund Will Continue 29-Year Tradition of Investing in Early-Stage Life Sciences and Information Technology Companies Firm Promotes Three Partners to General Partner MENLO PARK, Calif., Aug. 11 /PRNewswire/ --...                    

comments

                   

Anesiva Announces Second Quarter 2008 Financial Results and Update

redorbit.com     Aug 8, 2008   4 related          

Posted on: Thursday, 7 August 2008, 18:01 CDT SOUTH SAN FRANCISCO, Calif., Aug. 7 /PRNewswire-FirstCall/ -- "In addition, I'm pleased to report that our Phase 3 trials of Adlea(TM) for the management of acute pain following...                    

comments

                   

ARCA Biopharma Appoints James Carr As Vice President of Marketing

redorbit.com     Aug 1, 2008   2 related          

BROOMFIELD, Colo., Aug. 1 /PRNewswire/ -- ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced today that it has appointed...                    

comments